Rockefeller University

T cell attacking a cancer cell
#Antibodies #Immunotherapy #Oncology #Phase I trial #Rockefeller University

Immunotherapy drug eliminates aggressive cancers

A Phase I clinical trial of CD40 agonist antibody 2141-V11 has shown positive results, with six patients seeing their tumours shrink.  CD40 is a cell surface receptor and member of the tumour necrosis factor (TNF) receptor superfamily, proteins that are largely expressed by immune cells.  … Read More

#Cancer Research #News #Trending News